Experimental Cell-Drug combo takes on tough leukemia
NCT ID NCT06768476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether a new immune cell therapy called CART123, given together with the drug ruxolitinib, is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The study will enroll 12 adults who have no other curative options. Participants receive a single infusion of CART123 cells after a short course of ruxolitinib and chemotherapy. The main goal is to check for side effects and see if the combination is feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CART123 cells (a type of immune cell therapy) and ruxolitinib (a drug)
- What this could lead to
- If this works, it could point toward a new treatment option for people with hard-to-treat AML that has not responded to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, not effectiveness. The combination may cause serious side effects or fail to control the leukemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.